Semaglutide: difference between revisions
Diff·revision 29 → 30·14:54, 6 Oct 2025
Difference between revision 29 and revision 30 of Semaglutide. 3 lines changed; the page grew by 556 bytes.
| Revision 29 — 19:13, 12 Sep 2025 LiraLotte (talk) expand §Material sold outside licensed supply 9,799 bytes ±0 | Revision 30 — 14:54, 6 Oct 2025 StateBoardStace (talk) label the animal data as animal data in the sentence, not only in the section heading 10,355 bytes +556 | ||
|---|---|---|---|
| 70 | Documentation quality varies widely. A [[Certificate of analysis|certificate]] reporting only an [[Area percent purity|area percent]] figure does not establish how much semaglutide a vial contains: without a [[Peptide content|peptide content]] determination and a water figure by [[Karl Fischer titration|Karl Fischer titration]], the mass of active substance cannot be calculated, and a nominal 5 mg vial may contain considerably less.{{r|usp1503}} [[Underfilling|Underfilling]] is documented in independently tested material. | 70 | Documentation quality varies widely. A [[Certificate of analysis|certificate]] reporting only an [[Area percent purity|area percent]] figure does not establish how much semaglutide a vial contains: without a [[Peptide content|peptide content]] determination and a water figure by [[Karl Fischer titration|Karl Fischer titration]], the mass of active substance cannot be calculated, and a nominal 5 mg vial may contain considerably less.{{r|usp1503}} [[Underfilling|Underfilling]] is documented in independently tested material. |
| 71 | 71 | ||
| + | 72 | Acylated peptides are also analytically demanding. Their hydrophobicity requires a different gradient and often an elevated column temperature from that used for unmodified peptides, and a certificate that does not name its column and gradient cannot be assessed for adequacy. Community-submitted independent reports are collated at [[Third-party testing]]; they are self-selected and are not a survey.{{r|reports}} | |
| + | 73 | ||
| 72 | == References == | 74 | == References == |
| 73 | {{reflist}} | 75 | {{reflist}} |
| ⋮ | ⋮ | ||
| 77 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | 79 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> |
| 78 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 80 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 81 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 79 | 82 | ||
| 80 | == Further reading == | 83 | == Further reading == |